Most practitioners order a lipid panel and call it a day when it comes to cardiovascular risk assessment. But if you’re not checking homocysteine, you’re missing one of the most clinically actionable, and chronically underordered markers in your panel.
Elevated homocysteine is independently associated with cardiovascular disease, stroke, Alzheimer’s disease, and a host of other inflammatory conditions. And unlike many cardiovascular risk markers, when you find it elevated, you actually have meaningful therapeutic levers to pull. That’s the kind of marker worth knowing well.
What Is Homocysteine and Why Does It Accumulate?
Homocysteine is a sulfur-containing amino acid that sits at the intersection of the methylation cycle. To understand why it builds up, you need a working map of that cycle.
Here’s the short version: methionine (from dietary protein) is converted to S-adenosylmethionine (SAMe), the body’s primary methyl donor. As SAMe donates methyl groups to hundreds of downstream reactions, neurotransmitter synthesis, hormone clearance, DNA methylation, detoxification, it becomes S-adenosylhomocysteine (SAH), which is then cleaved to form homocysteine.
Under normal circumstances, homocysteine is efficiently recycled back into methionine via the methionine synthase pathway, a reaction that requires 5-methyltetrahydrofolate (5-MTHF) as its primary cofactor and active B12 (methylcobalamin) as the enzyme cofactor. A secondary remethylation pathway via betaine-homocysteine methyltransferase (BHMT) operates primarily in the liver and kidneys. Alternatively, homocysteine can be transsulfurated into cysteine via the CBS enzyme — a pathway that requires pyridoxine (B6) as a cofactor.
When any of these pathways are impaired, through nutrient deficiency, toxic burden, genetic polymorphism, or medication interference, homocysteine accumulates. And that accumulation is not benign.
The Clinical Consequences of Elevated Homocysteine
Homocysteine is directly cytotoxic to vascular endothelium. Elevated levels promote oxidative stress, impair nitric oxide synthesis, increase arterial stiffness, and promote a prothrombotic state. The research linking high homocysteine to major cardiovascular events is substantial and spans decades.
Beyond cardiovascular risk, elevated homocysteine has been associated with:
- Cognitive decline and Alzheimer’s disease — the VITACOG trial demonstrated that B-vitamin supplementation targeting homocysteine reduction significantly slowed brain atrophy in individuals with mild cognitive impairment
- Bone loss — homocysteine interferes with collagen cross-linking in bone matrix, increasing fracture risk independent of bone mineral density
- Pregnancy complications — including recurrent miscarriage, placental abruption, and neural tube defects
- Chronic kidney disease — impaired renal clearance of homocysteine creates a bidirectional feedback loop that accelerates vascular damage
- Depression and mood dysregulation — elevated homocysteine reflects impaired methylation of neurotransmitter synthesis pathways, particularly the SAMe-dependent production of dopamine, norepinephrine, and serotonin
What “Normal” Gets Wrong: The Case for a Functional Range
This is where conventional medicine consistently falls short. Standard laboratory reference ranges for homocysteine are typically reported as normal up to 15 µmol/L. Some labs set the upper limit as high as 17 or even 20 µmol/L.
The research tells a different story.
Cardiovascular risk begins to increase significantly at levels above 10 µmol/L, and multiple studies demonstrate increased risk of cognitive decline at levels well within the “normal” conventional range. The functional medicine reference range for homocysteine is 6–9 µmol/L, with an optimal target closer to 7 µmol/L. Levels above 9 µmol/L should prompt clinical attention, even when a conventional lab flags the result as normal.
This is not a minor distinction. A patient presenting at 13 µmol/L will be told their homocysteine is “fine” by most standard practitioners. A functional medicine lens tells us that patient is carrying meaningful cardiovascular and neurological risk — and that it is almost certainly addressable.
Root Causes: Why Is Homocysteine Elevated in the First Place?
One of the most powerful aspects of homocysteine as a clinical marker is that it functions as a downstream readout of methylation capacity. When you see it elevated, your next clinical question should always be: what is driving the impairment?
Nutrient deficiencies are the most common cause. B12 and folate are the primary drivers, both are essential cofactors for the remethylation of homocysteine back to methionine. B6 deficiency impairs the transsulfuration pathway. Riboflavin (B2) is a required cofactor for MTHFR enzyme activity. Zinc and magnesium also play supporting roles. Before reaching for high-dose supplementation, a thorough dietary and absorption history is warranted.
Genetic polymorphisms, particularly in MTHFR, are frequently implicated. The C677T variant (present in homozygous form in 8–20% of white populations and over 20% in some Hispanic populations) results in 70–75% loss of MTHFR enzyme activity, severely impairing the conversion of dietary folate to 5-MTHF, the active form required for homocysteine remethylation. The A1298C variant produces a 39% reduction in enzyme activity in homozygous form. Compound heterozygotes may lose up to 52% of enzyme activity. Importantly, genotype does not always correspond to functional methylation status, which is why testing the functional marker (homocysteine, MMA, RBC folate) matters more than genetic testing alone.
Medication interference is a frequently overlooked contributor. Proton pump inhibitors impair absorption of B12, folate and magnesium. Oral contraceptives deplete B vitamins (particularly B6 and B2) and magnesium, which are cofactors in methylation pathways. Metformin is a well-documented B12 depleter. Cholestyramine interferes with folate absorption. Nitrous oxide (used in dental procedures) oxidizes cobalamin and can precipitate acute functional B12 deficiency, particularly in patients who are already borderline replete.
Competition for methyl donors is a subtler but clinically important mechanism. When any single methylation pathway is under high demand (estrogen detoxification via COMT, histamine clearance via HNMT, catecholamine synthesis under chronic stress, immune activation driving T-cell maturation) available SAMe can be depleted preferentially for that pathway, leaving other functions, including homocysteine remethylation, underpowered. This is why patients under significant chronic stress, dealing with mold or heavy metal burden, or managing high estrogen states may present with elevated homocysteine even when their dietary intake of B vitamins appears adequate.
Gut absorption impairment deserves specific attention. B12 absorption is highly dependent on intrinsic factor secretion and an intact ileum. For adults over 50, or any patient with a history of GI dysfunction, atrophic gastritis, H. pylori, small intestinal disease, or bariatric surgery, absorption capacity may be dramatically reduced. Less than 1% of orally consumed B12 may be absorbed in these populations, making dietary intake data largely irrelevant to their actual functional status.
Building Your Methylation Marker Panel
Homocysteine does not exist in isolation. When elevated, it functions as a signal to investigate the broader methylation picture. The markers worth ordering together include:
Serum B12 — note that this is an unreliable standalone marker. Serum B12 can appear normal while functional B12 deficiency exists at the tissue level. It should never be used in isolation to rule out deficiency.
RBC folate — a far more accurate reflection of intracellular folate status than serum folate, which fluctuates with recent dietary intake and can be falsely elevated by certain conditions including hypothyroidism.
Serum folate — useful as part of the panel but interpret in context.
Serum MMA (methylmalonic acid) — a functional marker of B12 status at the cellular level. Elevated MMA confirms functional B12 deficiency even when serum B12 is within reference range. This is an inverse marker — high MMA signals deficiency.
Urine MMA and urine FIGLU — add-on markers for deeper methylation assessment. FIGLU (formiminoglutamic acid) accumulates when folate-dependent conversion is impaired and is a sensitive indicator of functional folate deficiency.
When reading these markers, apply a functional lens: a serum B12 below 450–500 pg/mL warrants clinical attention even if conventionally “normal,” and a homocysteine creeping above 9 µmol/L should not be dismissed simply because it hasn’t crossed the conventional threshold of 15.
Treatment: Starting With Diet, Not Supplements
The current trend in functional medicine leans heavily on high-dose methyl donor supplementation as a first-line intervention for elevated homocysteine. While supplementation clearly has a role, the clinical evidence warrants a more measured approach.
Methylation status is fundamentally a function of diet and lifestyle inputs. Starting there is both the safest and most sustainable approach.
A nutrient-dense dietary foundation should emphasize organ meats (liver is exceptional — one chicken liver provides approximately 254 mcg DFE of folate, beef liver approximately 215 mcg, and beef liver provides 83 mcg per 100g of B12), shellfish (clams deliver 99 mcg B12 per 100g, the single richest food source available), dark leafy greens, eggs, and quality animal protein to ensure methionine and cysteine sufficiency. Patients following Paleo or other whole-foods approaches who avoid fortified grains may be unknowingly under-consuming folate if they are not intentionally incorporating organ meats and abundant greens.
Address modifiable drivers simultaneously: evaluate and discontinue or mitigate medications that deplete methyl donors where clinically appropriate, screen for and treat underlying GI dysfunction impairing absorption, and assess and support stress physiology through the HPA axis.
When supplementation is warranted, avoid folic acid. Its conversion to the active THF form depends on dihydrofolate reductase, an enzyme with notably low activity in a significant proportion of the population. Unmetabolized folic acid accumulating in the systemic circulation has been associated in multiple studies with immune suppression, cognitive decline, anemia, and increased cancer risk. The appropriate supplemental forms are 5-MTHF (starting conservatively at 200–400 mcg/day rather than jumping to the 5–10 mg doses sometimes used) or folinic acid (5-formyl-THF) at 800 mcg/day, which is considerably better tolerated in patients who experience anxiety, agitation, or insomnia with 5-MTHF. Some patients respond well to one form and poorly to the other, clinical experimentation may be necessary.
For B12 supplementation, methylcobalamin or hydroxocobalamin are the preferred forms. Cyanocobalamin, the synthetic form used in most over-the-counter products, requires additional conversion steps and delivers cyanide as a byproduct, a clinically irrelevant concern at typical supplemental doses, but not the form of choice when you have better options.
Retest at 60 days to assess response. Once homocysteine is normalized, transition toward a dietary-first maintenance approach. In patients who cannot maintain optimal levels through diet alone, the clinical calculus becomes weighing ongoing cardiovascular and neurological risk from elevated homocysteine against the theoretical risks of long-term methyl donor supplementation, and in most cases, the former represents the greater and more immediate threat.
The Bigger Picture: Homocysteine as a Methylation Window
What makes homocysteine such a valuable clinical marker is what it reveals beyond cardiovascular risk. When you find it elevated, you are looking at a patient whose methylation capacity is under strain and methylation governs an extraordinary range of physiological functions.
Impaired methylation via SAMe depletion can compromise neurotransmitter synthesis, phase II liver detoxification, estrogen clearance through COMT, histamine breakdown, T-cell maturation, myelination of peripheral nerves, and mitochondrial energy production via CoQ10 and carnitine synthesis. A single elevated homocysteine result, read through a functional lens, opens a clinical conversation about depression, histamine intolerance, estrogen dominance, fatigue, immune dysregulation, and cardiovascular risk.
This is the power of functional blood chemistry interpretation, not simply identifying disease, but reading the terrain.
Ordering homocysteine is one of the highest-yield additions you can make to your standard blood chemistry panel. If it’s not already routine in your practice, the time to change that is now.
